DARPins: A true alternative to antibodies

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 2, 2007, Pages 153-159

  Stumpp, Michael T ^a,b   Amstutz, Patrick ^a  

^a MOLECULAR PARTNERS AG   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Ankyrin; Protein engineering; Repeat protein; Scaffold; Stability; Tumor targeting

Indexed keywords

DESIGNED ANKYRIN REPEAT PROTEIN; DESIGNED ANKYRIN REPEAT PROTEIN 1108 19; DESIGNED ANKYRIN REPEAT PROTEIN AR 3A; DESIGNED ANKYRIN REPEAT PROTEIN AR F8; DESIGNED ANKYRIN REPEAT PROTEIN E3 19; DESIGNED ANKYRIN REPEAT PROTEIN E3 5; DESIGNED ANKYRIN REPEAT PROTEIN G3; DESIGNED ANKYRIN REPEAT PROTEIN H6 2 A7; DESIGNED ANKYRIN REPEAT PROTEIN H6 2 B3; DESIGNED ANKYRIN REPEAT PROTEIN OFF7; KANAMYCIN; PROTEIN DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST CARCINOMA; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG DELIVERY SYSTEM; DRUG UPTAKE; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; GENE SEQUENCE; HUMAN; IMAGING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN LOCALIZATION; REVIEW; TECHNOLOGY; TUMOR LOCALIZATION; VALIDATION PROCESS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANKYRIN REPEAT; ANKYRINS; ANTIBODIES; ANTINEOPLASTIC AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PHARMACOLOGY;

EID: 33947305850     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Binz HK, Amstutz P, Plückthun A: Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 23(10):1257-1268.
2. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, Grütter MG, Plückthun A: High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol (2004) 22(5):575-582. •• The first report describing that DARPin libraries are an excellent source of non-immunoglobulin binding proteins.
3. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R et al: Initial sequencing and analysis of the human genome. Nature (2001) 409(6822):860-921.
4. Mosavi LK, Cammett TJ, Desrosiers DC, Peng ZY: The ankyrin repeat as molecular architecture for protein recognition. Protein Sci (2004) 13(6):1435-1448.
5. Pancer Z, Amemiya CT, Ehrhardt GR, Ceitlin J, Gartland GL, Cooper MD: Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey. Nature (2004) 430(6996):174-180. • Jawless vertebrates are reported to use repeat proteins for their adaptive immune response.
6. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol (2002) 20:197-216.
7. Forrer P, Stumpp MT, Binz HK, Plückthun A: A novel strategy to design binding molecules harnessing the modular nature of repeat proteins. FEBS Lett (2003) 539(1-3):2-6. • Describes the concept of designing repeat protein libraries.
8. Stumpp MT, Forrer P, Binz HK, Plückthun A: Designing repeat proteins: Modular leucine-rich repeat protein libraries based on the mammalian ribonuclease inhibitor family. J Mol Biol (2003) 332(2):471- 487.
9. Kajander T, Cortajarena AL, Regan L: Consensus design as a tool for engineering repeat proteins. Methods Mol Biol (2006) 340:151-170.
10. Michaely P, Tomchick DR, Machius M, Anderson RG: Crystal structure of a 12 ANK repeat stack from human ankyrinR. EMBO J (2002) 21(23):6387-6396.
11. Tanaka N, Nakanishi M, Kusakabe Y, Goto Y, Kitade Y, Nakamura KT: Structural basis for recognition of 2′,5′-linked oligoadenylates by human ribonuclease L. EMBO J (2004) 23(20):3929-3938.
12. Forrer P, Binz HK, Stumpp MT, Plückthun A: Consensus design of repeat proteins. Chembiochem (2004) 5(2):183-189.
13. Kohl A, Binz HK, Forrer P, Stumpp MT, Plückthun A, Grütter MG: Designed to be stable: Crystal structure of a consensus ankyrin repeat protein. Proc Natl Acad Sci USA (2003) 100(4):1700-1705.
14. Koren E, Zuckerman LA, Mire-Sluis AR: Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol (2002) 3(4):349-360.
15. Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, Jiskoot W: Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon α2b. Pharm Res (2005) 22(12):1997-2006.
16. Amstutz P, Koch H, Binz HK, Deuber SA, Plückthun A: Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries. Protein Eng Des Sel (2006) 19(5):219-229.
17. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W: Display technologies: Application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev (2006) 58(15):1622-1654.
18. Steiner D, Forrer P, Stumpp MT, Plückthun A: Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. Nat Biotechnol (2006) 24(7):823-831.
19. Amstutz P, Binz HK, Parizek P, Stumpp MT, Kohl A, Grütter MG, Forrer P, Plückthun A: Intracellular kinase inhibitors selected from combinatorial libraries of designed ankyrin repeat proteins. J Biol Chem (2005) 280(26):24715-24722. •• The first report demonstrating that DARPins can be used as intracellular inhibitors.
20. Kawe M, Forrer P, Amstutz P, Plückthun A: Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. J Biol Chem (2006) 281(52):40252-40263.
21. Sennhauser G, Amstutz P, Briand C, Storchenegger O, Grütter MG: Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol (2007) 5(1):e7 DOI: 10.1371/journal. pbio.0050007. •• The first report describing that DARPins can bind and inhibit membrane proteins.
22. Schrama D, Reisfeld RA, Becker JC: Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov (2006) 5(2):147-159.
23. Zahnd C, Pecorari F, Straumann N, Wyler E, Plückthun A: Selection and characterization of HER2 binding-designed ankyrin repeat proteins. J Biol Chem (2006), 281(46):35167-35175. •• The first report demonstrating that DARPins can be used in FACS and IHC assays.
24. Zahnd C: Designed ankyrin repeat proteins (DARPins) for tumor targeting: Biodistribution and pharmaco-kinetics of a HER2-binding DARPin. 23th International Conference of Advances in the Application of Monoclonal Antibodies in Clinical Oncology, Mykonos, Greece (2006).
25. Orlova A, Nilsson FY, Wikman M, Widstrom C, Stahl S, Carlsson J, Tolmachev V: Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med (2006) 47(3):512-519.
26. Chapman AP: PEGylated antibodies and antibody fragments for improved therapy: A review. Adv Drug Deliv Rev (2002) 54(4):531-545.
27. Schweizer A: CD4-specific designed ankyrin repeat proteins potently inhibit HIV entry. Keystone Symposium on HIV Pathogenesis, Keystone, Colorado, USA (2006).
28. Overall CM, Kleifeld O: Tumour microenvironment - opinion: Validating matrix metalloproteinases as drug targets and antitargets for cancer therapy. Nat Rev Cancer (2006) 6(3):227-239.
29. Marvin JS, Zhu Z: Bispecific antibodies for dual-modality cancer therapy: Killing two signaling cascades with one stone. Curr Opin Drug Discovery Dev (2006) 9(2):184-193. • A comprehensive review of bispecific antibodies in cancer therapy.
30. Pardridge WM: Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol (2006) 6(5):494-500.
31. Binz HK, Kohl A, Plückthun A, Grütter MG: Crystal structure of a consensus-designed ankyrin repeat protein: Implications for stability. Proteins (2006) 65(2):280-284.
32. Kohl A, Amstutz P, Parizek P, Binz HK, Briand C, Capitani G, Forrer P, Plückthun A, Grütter MG: Allosteric inhibition of aminoglycoside phosphotransferase by a designed ankyrin repeat protein. Structure (Camb) (2005) 13(8):1131-1141.